Celltrion

- Full-scale expansion review for product (Remsima, Truxima, etc.) production and CMO requests for global pharmaceutical companies

- Scheduled to expand up to 170,000 liters ... Expansion of production capacity of 311,000 liters including first and third plants

[May 25, 2016] Celltrion is planning to expand its third plant in Song Do this year. Celltrion held a board meeting on May 25th to expand the capacity of the first and third plants to respond to the production of successful products, including Remsima, Truxima, Herzuma, and to respond to a request for CMO production from existing CMO customers and global pharmaceutical companies.

Celltrion is anticipated to have a shortage of equipment due to increased production volume, including the supply of antibody biosimilar Remsima in the US and additional volume due to the favorable market in Europe, and supply of additional volume due to additional indication of Inflammatory Bowel Disease in Canada, etc. Truxima and other follow-on products are scheduled for approval by the end of this year. Truxima and other follow-on products are scheduled for approval by the end of this year, and the company plans to expand production capacity by the end of this year.

Celltrion is planning to invest about KRW 325.1 billion and plans to increase the capacity of the third plant to 120,000 liters and the capacity of the existing first plant to 50,000 liters. The first plant is expected to be completed in 2018, starting commercial production in 2019, and the third plant is expected to be completed in 2019, starting commercial production in 2021.

If Celltrion expands production capacity by 170,000 liters, it will reach 310,000 liters after completion. Celltrion currently has a total of 140,000 liters of biopharmaceutical production facilities, including 50,000 liters for the first plant and 90,000 liters for the second plant.

 
A Celltrion official made a statement: "We have received requests to produce biopharmaceuticals from a number of global pharmaceutical companies, and we have selected our clients considering the high production efficiency and profitability and have been engaged in commissioned production business. Celltrion is responding flexibly to the growing demand for biosimilars, which are developed in-house and produced through expansion," said the official, "based on the confidence of high quality and mass production capability, we will be positioned as a leader in the biopharmaceutical industry."